These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17391068)

  • 21. Pharmacogenomics: historical perspective and current status.
    Charlab R; Zhang L
    Methods Mol Biol; 2013; 1015():3-22. PubMed ID: 23824846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of postmarketing surveillance in contemporary medicine.
    Woodcock J; Behrman RE; Dal Pan GJ
    Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenomics and active surveillance for serious adverse drug reactions in children.
    Loo TT; Ross CJ; Sistonen J; Visscher H; Madadi P; Koren G; Hayden MR; Carleton BC
    Pharmacogenomics; 2010 Sep; 11(9):1269-85. PubMed ID: 20860467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving reporting of adverse events and adverse drug reactions following injections of Chinese materia medica.
    Bian ZX; Tian HY; Gao L; Shang HC; Wu TX; Li YP; Zhang BL; Song L
    J Evid Based Med; 2010 Feb; 3(1):5-10. PubMed ID: 21349034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biobanking and pharmacogenomics.
    McCarty CA; Wilke RA
    Pharmacogenomics; 2010 May; 11(5):637-41. PubMed ID: 20415552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is the yellow card road going in the right direction?
    Evans SJ
    Drug Saf; 2015 Jun; 38(6):517-8. PubMed ID: 25948507
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug safety special: chasing shadows.
    Frantz S
    Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacogenomics of severe cutaneous adverse reactions.
    Kaniwa N; Saito Y
    Pharmacogenomics; 2013 Apr; 14(6):595-8. PubMed ID: 23570461
    [No Abstract]   [Full Text] [Related]  

  • 29. Intussusception alert.
    Farr C
    Nursing; 2007 Apr; 37(4):10. PubMed ID: 17413328
    [No Abstract]   [Full Text] [Related]  

  • 30. Advances in the pharmacogenomics of adverse drug reactions.
    Alvarado I; Wong ML; Licinio J
    Pharmacogenomics J; 2002; 2(5):273. PubMed ID: 12439730
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting.
    Tsong Y
    J Biopharm Stat; 1995 Mar; 5(1):95-114. PubMed ID: 7613562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
    Souayah N; Nasar A; Suri MF; Qureshi AI
    J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse drug reactions: monitoring, reporting and prevention.
    Munasinghe TM
    Ceylon Med J; 2002 Mar; 47(1):19-21. PubMed ID: 12001600
    [No Abstract]   [Full Text] [Related]  

  • 34. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA.
    Lesko LJ; Zineh I
    Pharmacogenomics; 2010 Apr; 11(4):507-12. PubMed ID: 20350131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defining the opportunity for pharmacogenetic intervention in primary care.
    Grice GR; Seaton TL; Woodland AM; McLeod HL
    Pharmacogenomics; 2006 Jan; 7(1):61-5. PubMed ID: 16354125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse drug reactions in hospital and in the community.
    D'Arcy PF
    Adverse Drug React Toxicol Rev; 1997 Jun; 16(2):95-101. PubMed ID: 9359931
    [No Abstract]   [Full Text] [Related]  

  • 37. EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions.
    Molokhia M; McKeigue P
    Pharmacogenomics; 2006 Jun; 7(4):633-8. PubMed ID: 16753010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are we talking to the right people?
    Alden CL
    Toxicol Pathol; 1999; 27(2):243. PubMed ID: 10207989
    [No Abstract]   [Full Text] [Related]  

  • 39. The future of population-based postmarket drug risk assessment: a regulator's perspective.
    Hammad TA; Neyarapally GA; Iyasu S; Staffa JA; Dal Pan G
    Clin Pharmacol Ther; 2013 Sep; 94(3):349-58. PubMed ID: 23739537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is primary care ready for pharmacogenetics?
    Voora D; Gage BF
    Pharmacogenomics; 2006 Jan; 7(1):1-3. PubMed ID: 16354118
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.